NCT01079013Unknown2 期
Phase II Trial of Fludarabine Combined With Intravenous Treosulfan and Allogeneic Hematopoietic Stem-cell Transplantation in Patients With Lymphatic Malignancies
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- disease-free survival
研究概览
简要总结
The study hypotheses is that the introduction of dose escalated treosulfan, in substitution to busulfan or melphalan, will reduce toxicity after allogeneic transplantation while improving disease eradication in patients with lymphoid malignancies not eligible for standard transplantation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 68 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age less than physiologic 68 years.
- •Patients with NHL and HL with an indication for allogeneic transplantation as follows:
- •Aggressive lymphoma and Hodgkin lymphoma; relapse after autologous transplants
- •Follicular lymphoma; failure of at least one prior regimen
- •Disease must be at chemo-sensitive or stable status to prior therapy before transplant.
- •Patients must have an HLA matched related or unrelated donor willing to donate either peripheral blood stem cells or bone marrow. Matching is based on high-resolution class I (HLA-A, -B, -C) and class II (HLA-DRB1, -DQB1) typing. The goal is to transplant > 3 x 106 CD34+ cells per kg body weight of the recipient
- •Patients must sign written informed consent
- •Adequate birth control in fertile patients
排除标准
- •Overt progressive disease prior to transplantation.
- •Bilirubin > 3.0 mg/dl, transaminases > 3 times upper normal limit
- •Creatinine > 2.0 mg/dl
- •ECOG-Performance status > 2
- •Uncontrolled infection
- •Pregnancy or lactation
- •Abnormal lung diffusion capacity (DLCO < 40% predicted)
- •Severe cardiovascular disease
- •CNS disease involvement
- •Pleural effusion or ascites > 1 liter
- •Known hypersensitivity to fludarabine or treosulfan
- •Psychiatric conditions/disease that impair the ability to give informed consent or to adequately co-operate
研究组 & 干预措施
treosulfan
Experimental
干预措施: treosulfan (Drug)
结局指标
主要结局
disease-free survival
时间窗: 2 years after transplantation
次要结局
- relapse(2 year after transplantation)
- overall survival(2 year after transplantation)
- treatment-related mortality(2 year after transplantation)
- GVHD(2 year after transplantation)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Treosulfan-based Conditioning for Transplantation in AML/MDSAcute Myeloid LeukemiaMyelodysplastic SyndromeNCT00491634Dr. Avichai Shimoni MD24
Unknown
2 期
Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid MalignanciesNon Hodgkin LymphomaMultiple MyelomaChronic Lymphocytic LeukemiaHodgkin LymphomaNCT02507479Sheba Medical Center24
Unknown
2 期
Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaAcute Myeloid Leukemia in RemissionMyelodysplastic/Myeloproliferative NeoplasmMyelodysplastic/Myeloproliferative Neoplasm, UnclassifiableMinimal Residual DiseaseMyelodysplastic SyndromeChronic Myelomonocytic LeukemiaNCT01894477Fred Hutchinson Cancer Center102
已完成
2 期
Study of Stem Cell Transplant for Leukemia and Myelodysplastic Syndromes Using Clofarabine and Busulfan RegimenLeukemiaMyelodysplastic SyndromeNCT00852163Baylor Research Institute20
已完成
2 期
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine ConditioningAcute Lymphocytic LeukemiaChronic Myeloid LeukemiaMyeloproliferative DiseasesNon-Hodgkins LymphomaLeukemiaAcute Myeloid LeukemiaChronic Lymphocytic LeukemiaHodgkins LymphomaMultiple MyelomaMyelodysplastic SyndromeNCT01572662M.D. Anderson Cancer Center201